Ykov VJ, Rinne T, Zhang Q et al. APR-246/PRIMA-1(MET) rescues epidermal differentiation in skin keratinocytes derived from EEC syndrome sufferers with p63 mutations. Proc Natl Acad Sci USA 2013; 110: 2157?162. 20. Lehmann S, Bykov VJ, Ali D, Andren O, Cherif H, Tidefelt U et al. Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol 2012; 30: 3633?639. 21. Lambert JM, Gorzov P, Veprintsev DB, Soderqvist M, Segerback D, Bergman J et al. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell 2009; 15: 376?88. 22. Arner ES. Concentrate on mammalian thioredoxin reductases ?important selenoproteins with versatile functions. Biochim Biophys Acta 2009; 1790: 495?26. 23. Arne ESJ. Selenoproteins ?What unique properties can arise with selenocysteine in spot of cysteine? Exp Cell Res 2010; 316: 1296?303. 24. Sasada T, Nakamura H, Ueda S, Sato N, Kitaoka Y, Gon Y et al. Attainable involvement of thioredoxin reductase as well as thioredoxin in cellular sensitivity to cis-diamminedichloroplatinum (II). No cost Radic Biol Med 1999; 27: 504?14. 25. Tonissen KF, Di Trapani G. Thioredoxin program inhibitors as mediators of apoptosis for cancer therapy. Mol Nutr Food Res 2009; 53: 87?03. 26. Anestal K, Arner ES. Rapid induction of cell death by selenium-compromised thioredoxin reductase 1 but not by the completely active enzyme containing selenocysteine. J Biol Chem 2003; 278: 15966?5972. 27. Anestal K, Prast-Nielsen S, Cenas N, Arner ES. Cell death by SecTRAPs: thioredoxin reductase as a prooxidant killer of cells. PLoS 1 2008; 3: e1846. 28. Arne ESJ, Holmgren A. Measurement of thioredoxin and thioredoxin reductase. In: Costa LG (ed) Present Protocols in Toxicology. Wiley: Hoboken, NJ, USA, 2000.2-Chloro-5-hydrazinylpyrazine Chemical name pp 7.Dibutyl sulfide web four.PMID:23912708 1?.four.14. 29. Ramqvist T, Magnusson KP, Wang Y, Szekely L, Klein G, Wiman KG. Wild-type p53 induces apoptosis in a Burkitt lymphoma (BL) line that carries mutant p53. Oncogene 1993; eight: 1495?500. 30. Witte AB, Anestal K, Jerremalm E, Ehrsson H, Arner ES. Inhibition of thioredoxin reductase but not of glutathione reductase by the key classes of alkylating and platinum-containing anticancer compounds. Cost-free Radic Biol Med 2005; 39: 696?03. 31. Fang J, Lu J, Holmgren A. Thioredoxin reductase is irreversibly modified by curcumin. J Biol Chem 2005; 280: 25284?5290. 32. Lu J, Papp LV, Fang J, Rodriguez-Nieto S, Zhivotovsky B, Holmgren A. Inhibition of mammalian thioredoxin reductase by some flavonoids: implications for myricetin and quercetin anticancer activity. Cancer Res 2006; 66: 4410?418. 33. Biaglow JE, Miller RA. The thioredoxin reductase/thioredoxin method: novel redox targets for cancer therapy. Cancer Biol Ther 2005; four: 6?three. 34. Prigge JR, Eriksson S, Iverson SV, Meade TA, Capecchi MR, Arner ES et al. Hepatocyte DNA replication in expanding liver needs either glutathione or perhaps a single allele of txnrd1. Free Radic Biol Med 2012; 52: 803?ten. 35. Bondareva AA, Capecchi MR, Iverson SV, Li Y, Lopez NI, Lucas O et al. Effects of thioredoxin reductase-1 deletion on embryogenesis and transcriptome. Free Radic Biol Med 2007; 43: 911?23. 36. Suvorova ES, Lucas O, Weisend CM, Rollins MF, Merrill GF, Capecchi MR et al. Cytoprotective Nrf2 pathway is induced in chronically txnrd 1-deficient hepatocytes. PLoS 1 2009; four: e6158. 37. Mandal PK, Schneider M, Kolle P, Kuhlencordt P, Forster H, Beck H et al. Loss of thioredoxin reductase 1 renders tumors.